Articles

In the last four issues, we discussed a new software that can go through over 6 million possible treatments using anywhere from 1 to 5 drugs for an effective treatment for type 2 diabetes. Along with determining the best treatment for the patient, it includes the ability to put in what the patient can afford in their budget. Dr. John Interlandi, one of our readers, has submitted a counterpoint to using this software to decide the best treatment options. In Part 1, Dr. Interlandi shares his concerns about the use of AI in medical decision making. 

Short-term efficacy and safety of SGLT2 inhibitors have been well established, but what happens with long-lasting use of these medications?

30-year study shows effects of breastfeeding on diabetes incidence in women of child-bearing age.

GLP-1 agonists randomized showdown. Which agent is better?

Evaluating if bolus calculators for insulin pumps can be accurately calibrated by speech recognition.

A study examining the timing of foods and its associated risk to islet autoimmunity.

Does adding Zetia to a multifaceted drug therapy regimen help improve health outcomes?

A closer look into what’s new according to the WHO shows if more women are at risk for gestational diabetes than thought.

Letting your patients know how long they may survive and how to extend their survival time can get your patients to increase their physical activity or get them to start.

T2D diagnosed within last 6 years may be able to achieve remission if substantial weight loss is achieved.